ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 35.1 Cr.
- Current Price ₹ 26.8
- High / Low ₹ 62.8 / 21.0
- Stock P/E
- Book Value ₹ 54.5
- Dividend Yield 0.00 %
- ROCE 1.48 %
- ROE -10.6 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.49 times its book value
Cons
- Company has low interest coverage ratio.
- Contingent liabilities of Rs.15.7 Cr.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 184 days.
- Working capital days have increased from 128 days to 199 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 154 | 354 | 220 | 145 | 114 | |
| 140 | 286 | 205 | 135 | 112 | |
| Operating Profit | 14 | 68 | 15 | 10 | 2 |
| OPM % | 9% | 19% | 7% | 7% | 2% |
| 1 | 1 | 10 | -1 | -0 | |
| Interest | 4 | 9 | 12 | 11 | 10 |
| Depreciation | 1 | 6 | 9 | 8 | 7 |
| Profit before tax | 10 | 54 | 3 | -11 | -16 |
| Tax % | 31% | 25% | 110% | -5% | |
| 7 | 40 | -0 | -10 | -14 | |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -10.72 |
| Dividend Payout % | 0% | 3% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | -49% |
| 1 Year: | -53% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | 13 |
| Reserves | 73 | 73 | 63 | 58 |
| 77 | 71 | 73 | 85 | |
| 130 | 119 | 92 | 86 | |
| Total Liabilities | 290 | 276 | 241 | 242 |
| 93 | 88 | 58 | 59 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 198 | 188 | 183 | 183 | |
| Total Assets | 290 | 276 | 241 | 242 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 25 | 26 | -9 | ||
| -44 | -9 | 20 | ||
| 20 | -17 | -10 | ||
| Net Cash Flow | 0 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 105 | 138 | 184 | |
| Inventory Days | 59 | 118 | 183 | |
| Days Payable | 113 | 165 | 254 | |
| Cash Conversion Cycle | 51 | 91 | 113 | |
| Working Capital Days | 78 | 107 | 199 | |
| ROCE % | 9% | 1% |
Documents
Announcements
-
Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November, 2018- Fund Raising By Issuance Of Debt Securities By Large Corporate (LC)
24 Apr - ANG Lifesciences confirms non-applicability of SEBI circular for large entities as of March 31, 2025.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
24 Apr - ANG Lifesciences confirms non-applicability of SEBI circular for large corporates as of March 31, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
22 Apr - Certificate confirming securities dematerialization compliance for quarter ended March 31, 2025.
-
Closure of Trading Window
1 Apr - Closure of trading window for insider trading.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
20 Mar - Investor meeting held with Milin Ramani.
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)